ArticleRadiologie (Heidelberg, Germany)2026
A functionally guided fusion Vision Transformer for predicting IDH status in gliomas: a multicenter study with external validation and incomplete multimodal evaluation.
Article in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate preoperative prediction of isocitrate dehydrogenase (IDH) genotype in gliomas is crucial for treatment planning and prognostic evaluation. However, variability across imaging modalities and centers limits model generalization in clinical practice. PURPOSE: We aimed to develop and evaluate a functionally guided fusion Vision Transformer (FGF-ViT) network for IDH genotype prediction in gliomas and to assess its generalization across multicenter datasets and incomplete multimodal inputs.
methodsThis retrospective multicenter study involved glioma patients from multiple institutions. In step 1, four FGF-ViT networks were constructed using different modality combinations (conventional MRI [cMRI]; MRI + diffusion-weighted imaging [DWI]; cMRI + perfusion-weighted imaging [PWI]; cMRI + DWI + PWI), trained on a primary cohort, and tested on an independent external validation set. Step 2 evaluated model generalization on additional multicenter datasets with variable modality availability. Models fused cMRI, DWI, and DSC-PWI features via transformer attention. Performance was assessed using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.
resultsThe FGF-ViT achieved robust IDH prediction with an AUC of 0.822 (95% CI: 0.666-0.977) in the independent external validation cohort. Its performance remained stable even with one missing functional modality.
conclusionThe proposed FGF-ViT provides a clinically relevant multimodal imaging and generalizable framework for preoperative IDH genotype prediction in gliomas, enabling reliable application across centers and incomplete multimodal conditions.
Indexed as
Identifiers
42307635What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.